A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques

Journal of Infectious Diseases

Volumn 207, Issue 8, 2013, Pages 1316-1327

  Safronetz, David ^a   Strong, James E ^e,f,g   Feldmann, Friederike ^b   Haddock, Elaine ^a   Sogoba, Nafomon ^h   Brining, Douglas ^c   Geisbert, Thomas W ^d   Scott, Dana P ^c   Feldmann, Heinz ^a,g  

^a Laboratory of Virology   (Canada)

^b Office of Operations and Management   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f Department of Pediatrics and Child Health ^*  (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h UNIVERSITY OF BAMAKO   (Mali)

Author keywords

disease modeling; guinea pigs; Lassa fever; non human primates; pathogenesis; West Africa

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL FEATURE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GUINEA PIG; IMMUNE RESPONSE; LASSA FEVER; LASSA VIRUS; LIBERIA; MACACA FASCICULARIS; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIERRA LEONE; VIRAL TROPISM; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; CERCOPITHECUS AETHIOPS; CHEMOKINE CCL3; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GUINEA PIGS; HEMATOLOGIC TESTS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; INTERLEUKIN-6; LASSA FEVER; LASSA VIRUS; LUNG; MACACA FASCICULARIS; MALE; MALI; RNA, VIRAL; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VERO CELLS; VIRAL LOAD; VIREMIA; VIRULENCE;

EID: 84875582037     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit004     Document Type: Article

References (41)

1. McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987; 155: 445-55.
2. Frame JD. Clinical features of Lassa fever in Liberia. Rev Infect Dis 1989; 11(Suppl 4):S783-9.
3. Bausch DG, Demby AH, Coulibaly M, et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 2001; 1:269-81.
4. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African subregion: an overview. J Vect Borne Dis 2007; 44:1-11.
5. Gunther S, Emmerich P, Laue T, et al. Imported Lassa fever in Germany: molecular characterization of a new Lassa virus strain. Emerg Infect Dis 2000; 6:466-76.
6. Atkin S, Anaraki S, Gothard P, et al. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveil 2009; 14:pii:19145.
7. Safronetz D, Lopez J, Sogoba N, et al. Detection of Lassa virus, Mali. Emerg Infect Dis 2010; 16:1123-6.
8. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987; 155:437-44.
9. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practices. Br Med J 1995; 311:857-9.
10. Gunther S, Lenz O. Lassa virus. Crit Rev Clin Lab Sci 2004; 41: 339-90.
11. Gowen BB, Holbrook MR. Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses. Antiviral Res 2007; 78: 79-90.
12. Walker DH, Wulff H, Lange JV, Murphy FA. Comparative pathology of Lassa virus infection in monkeys, guinea pigs, and Mastomys natalensis. Bull World Health Organ 1975; 52:523-34.
13. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 1980; 141:580-9.
14. Callis RT, Jahrling PB, DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg 1982; 31:1038-45.
15. Lange JV, Mitchell SW, McCormick JB, Walker DH, Evatt BL, Ramsey RR. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus infected monkeys. Am J Trop Med Hyg 1985; 34:999-1007.
16. Fisher-Hoch SP, Mitchell SW, Sasso DR, Lange JV, Ramsey R, McCormick JB. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis 1987; 155:465-74.
17. Geisbert TW, Jones S, Fritz E, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 6:e183.
18. Hensley LE, Smith MA, Geisbert JB, et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol J 2011; 8:205.
19. Wulff H, Johnson KM. Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa and Marburg virus infections. Bull WHO 1979; 57:631-5.
20. Jahrling PB, Frame JD, Smith SB, Monson MH. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans R Soc Trop Med Hyg 1985; 79:374-9.
21. Brining D, Mattoon J, Kercher L, et al. Thoracic radiography as a refinement methodology for the study of H1N1 influenza in the cynomolgus macaque (Macaca fascicularis) model. Comp Med 2010; 60:389-95.
22. Ebihara H, Rockx B, Marzi A, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis 2011; 204:S991-9.
23. Falzarano D, Feldmann F, Grolla A, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 2011; 204:S1082-9.
24. Vieth S, Drosten C, Lenz O, et al. RT-PCR for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans R Soc Trop Med Hyg 2007; 101:1253-64.
25. Branco LM, Matschiner A, Fair JN, et al. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol J 2008; 5:74.
26. Mahanty S, Bausch DG, Thomas RL, et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 2001; 183:1713-21.
27. Baize S, Marianneau P, Loth P, et al. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J Virol 2009; 83:5890-903.
28. Sogoba N, Feldmann H, Safronetz D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health 2012; 59(Suppl 2):43-7.
29. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170:2797-801.
30. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages in productive but fails to activate cells. J Immunol 2004; 172:2861-9.
31. Lukashevich IS, Maryankova R, Vladyko AS, et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-α gene expression. J Med Virol 1999; 59:552-60.
32. Qi X, Lan S, Wang W, et al. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 2010; 468:779-83.
33. Hastie KM, Kimberlin CR, Zandonatti MA, MacRae IJ, Ollmann Saphire E. Structure of the Lassa virus nucelprotein reveals a dsRNAspecific 3? to 5? exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 2011; 108:2396-401.
34. Feldmann H, Bugani H, Mahner F, Klenk HD, Drenckhahn Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages. J Virol 1996; 70:2208-14.
35. Bowen MD, Rollin PE, Ksiazek TG, et al. Genetic diversity among Lassa virus strains. J Virol 2000; 74:6992-7004.
36. Macher AM, Wolfe MS. Historical Lassa fever reports and 30-year clinical update. Emerg Infect Dis 2006; 12:835-7.
37. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20-6.
38. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51:1435-41.
39. Lukashevich IS, Patterson J, Carrion R, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005; 79:13934-42.
40. Cashman KA, Smith MA, Twenhafel NA, et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res 2011; 90:70-9.
41. Jiang X, Dalebout TJ, Bredenbeek PJ, et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 2011; 29:1248-57.